NCT04916925

Brief Summary

effect of vitamin D oral supplementation in poly csytic ovarian women resistant to clomiphene citrate

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Aug 2021

Shorter than P25 for phase_1

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 21, 2019

Completed
1.9 years until next milestone

First Posted

Study publicly available on registry

June 8, 2021

Completed
2 months until next milestone

Study Start

First participant enrolled

August 21, 2021

Completed
11 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2021

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2021

Completed
Last Updated

June 8, 2021

Status Verified

June 1, 2021

Enrollment Period

11 days

First QC Date

July 21, 2019

Last Update Submit

June 1, 2021

Conditions

Keywords

Poly cystic ovary syndromeVitamin D

Outcome Measures

Primary Outcomes (1)

  • number of the ovulated follicles

    Number of ovulated follicles by trans vaginal ultra sound signs of ovulation

    36 hours of taking HCG injection

Secondary Outcomes (2)

  • pregancy rate

    2 days after delayed menses

  • Evaluation of the endometrial thickness

    36 hour of taking HCG

Study Arms (1)

pcos resistant to cc plus vit d

EXPERIMENTAL

100 patients who are PCOS and resist CC will receive Vitamin D 10000 IU orally plus 150mg clomid orally for 3 months number and size of growing follicles will be monitored

Drug: Vitamin DDrug: Clomid

Interventions

Adding vitamin D to PCOS patients who are resistant to clomiphene regime for induction will or not improve the Clinical pregnancy rate and will or not increase chances of ovulation and pregnancy.

pcos resistant to cc plus vit d
ClomidDRUG

CLOMID is adrug used for ovulation induction

pcos resistant to cc plus vit d

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility Detailsin child bearing age
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Age: 18-40 years 2- Polycystic ovarian syndrome diagnosis made according to ESHRE/ASRM criteria.
  • Polycystic ovaries (either 12 or more follicles or increased ovarian volume \[\> 10 cm3
  • Oligo-ovulation or anovulation
  • Clinical and/or biochemical signs of hyperandrogenism (Azziz, 2006). 3- PCOS infertile women resistant to CC for 3 cycles. clomiphene citrate resistance means failure to ovulate with 3 months use of clomid at 150 mg/day for 5 days

You may not qualify if:

  • Causes of infertility other than PCOS.
  • Male factor.(normal semen analysis)
  • Other factors e.g. endometriosis
  • Tubal factor. (normal hysterosalpingography)
  • Premature ovarian failure: Day 3 FSH \> 14 mlu/ml or antimullerian hormone \<1 ng/ml.
  • Normal ultrasound except for criteria of PCO
  • Causes of anovulation other than PCOS.
  • Patients with hyperprolactinemia
  • Patients with thyroid dysfunction.
  • Current or in last six months use of vit D treatment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Vitamin D DeficiencyPolycystic Ovary Syndrome

Interventions

Vitamin DClomiphene

Condition Hierarchy (Ancestors)

AvitaminosisDeficiency DiseasesMalnutritionNutrition DisordersNutritional and Metabolic DiseasesOvarian CystsCystsNeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesGonadal DisordersEndocrine System Diseases

Intervention Hierarchy (Ancestors)

SecosteroidsSteroidsFused-Ring CompoundsPolycyclic CompoundsStilbenesBenzylidene CompoundsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic Chemicals

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: a single arm clinical trail
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Clinical gynecology professor

Study Record Dates

First Submitted

July 21, 2019

First Posted

June 8, 2021

Study Start

August 21, 2021

Primary Completion

September 1, 2021

Study Completion

December 1, 2021

Last Updated

June 8, 2021

Record last verified: 2021-06